Dr. Clete Barrick breaks down the most important GLP-1 research presented at the European Congress on Obesity 2026 in Istanbul, and what each finding means for patients on Ozempic, Wegovy, Mounjaro, and Zepbound right now.

He covers the new higher-dose Wegovy data (7.2 mg), the maintenance dosing trial Zepbound patients have been waiting for, what happens when you switch from an injection to an oral pill, the real-world data showing half of patients quit before they get the benefit, and the Viking Therapeutics oral pill that may compete with injectable tirzepatide by 2028.

Each study gets the same three-beat treatment: what happened, why you should care, and what you should do about it.

In this episode:

• STEP UP: Wegovy 7.2 mg delivers 20.7% weight loss, with responders hitting 27.7%
• Medicare BRIDGE program adding Wegovy 7.2 on July 1
• SURMOUNT-MAINTAIN: 5 mg tirzepatide as a legitimate maintenance dose
• Why the dose ladder mental model is wrong
• ATTAIN-MAINTAIN: Switching from Wegovy to oral orforglipron (Foundayo) vs. switching from Zepbound
• Why the GIP receptor matters when you change medications
• Wilding real-world data: 50% discontinuation, dose-dependent metabolic benefits
• The most important variable in GLP-1 treatment (it's not which drug)
• Viking VK2735: 12.2% loss in 13 weeks from an oral dual agonist
• What the pill landscape looks like in 2028

New episodes weekly. Subscribe and visit barrickhealth.com for physician-led GLP-1 care.

Everything discussed in this episode is education, not medical advice for your specific situation. Talk to your prescriber before making changes to your treatment.

LINKS

barrickhealth.com https://www.youtube.com/@BarrickHealth

TAGS/KEYWORDS

(Paste into Buzzsprout tags field, comma-separated)

ECO 2026, European Congress on Obesity, STEP UP trial, Wegovy 7.2, SURMOUNT-MAINTAIN, tirzepatide maintenance dose, Zepbound maintenance, ATTAIN-MAINTAIN, orforglipron, Foundayo, Viking VK2735, VENTURE-2, Wilding real-world data, GLP-1 discontinuation, GLP-1 news, oral GLP-1 pill, Medicare BRIDGE program, semaglutide vs tirzepatide, dual agonist, GIP receptor, obesity medicine, Dr. Clete Barrick, Straight Shot podcast

REFERENCES CITED

• STEP UP trial. Higher-dose semaglutide 7.2 mg for obesity. Presented at European Congress on Obesity (ECO) 2026, Istanbul. Novo Nordisk.
• Wadden TA, et al. Tirzepatide for maintenance of weight reduction (SURMOUNT-MAINTAIN). The Lancet. 2026.
• ATTAIN-MAINTAIN trial. Transition from injectable semaglutide or tirzepatide to oral orforglipron. Presented at ECO 2026, Istanbul. Eli Lilly.
• Wilding JPH, et al. Real-world discontinuation and metabolic outcomes of GLP-1 receptor agonists in 90,000 patients (UK/EU). Presented at ECO 2026, Istanbul.
• VENTURE-2 trial. Phase 2 results for oral dual GLP-1/GIP agonist VK2735. Presented at ECO 2026, Istanbul. Viking Therapeutics.
• Medicare BRIDGE Program formulary update, effective July 1, 2026.

Dr. Clete Barrick, board-certified in internal medicine and obesity medicine, prescribes these medications every day and takes tirzepatide himself. In this episode, he walks through what the University of Pennsylvania researchers actually found, why the methodology matters, and where every headline got it wrong.

You'll hear the truth about the 13% psychiatric symptom finding, why menstrual changes and cold sensitivity aren't "hidden" at all, and the real story buried under the clickbait: the system for catching side effects is broken. Includes counter-data from The Lancet Psychiatry and Nature Medicine showing GLP-1s are associated with lower mental health risk, not higher.

If you want a physician who actually monitors all of this, book a free consult at barrickhealth.com. Subscribe for weekly evidence-based GLP-1 content from a doctor who's been on the medication.

YouTube: youtube.com/@BarrickHealth

In this episode, he covers the real differences between single and dual agonist medications, the head-to-head SURMOUNT-5 trial results, side effect profiles (including the birth control interaction most providers miss), who actually does better on which medication, and why the best GLP-1 is the one you can afford to stay on.

He also addresses compounding costs, why semaglutide is sometimes the smarter pick despite tirzepatide's stronger averages, the oral Wegovy option for patients with needle phobia, and the fear-mongering around FDA regulatory moves that's driving patients to make bad decisions.

In this episode:

• Single vs. dual agonist: what the mechanism difference actually means
• SURMOUNT-5 and the 2026 Bernardi meta-analysis (28 trials, 34,000 patients)
• Why averages hide a massive spread in individual responses
• GI side effects compared (and why tirzepatide is often better tolerated)
• The birth control absorption warning (59% reduction with tirzepatide)
• Autoimmune conditions, migraines, and PCOS: which medication has the edge
• Compounding costs: semaglutide vs. tirzepatide pricing reality
• The sledgehammer vs. Michelangelo analogy
• Why you shouldn't switch medications based on social media fear

New episodes weekly. Subscribe and visit barrickhealth.com for physician-led GLP-1 care.

Everything discussed in this episode is education, not medical advice for your specific situation. Talk to your prescriber before making changes to your treatment.

LINKS: barrickhealth.com https://www.youtube.com/@BarrickHealth

REFERENCES CITED:

• Jastreboff AM, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025.
• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
• Bernardi S, et al. Network meta-analysis of tirzepatide vs semaglutide (28 RCTs, 34,367 patients). J Diabetes. 2026.
• Mounjaro prescribing information: oral contraceptive absorption interaction data.

Dr. Clete Barrick breaks down how these medications work at three job sites: your pancreas, your stomach, and (most importantly) your brain. He explains the difference between homeostatic hunger and hedonic hunger, why GLP-1s quiet "food noise" through the brain's reward circuit, and why the "you only lose weight because you feel sick" myth is flat wrong.

In this episode:

• GLP-1: the hormone you already make
• Three job sites: pancreas, stomach, brain
• Homeostatic vs. hedonic hunger (the car wash sign analogy)
• Why less than 1% of weight loss comes from nausea
• Semaglutide vs. tirzepatide: what's different
• What GLP-1s don't do
• The Straight Shot: you are not cheating

No biochemistry degree required. Just the science you need to understand what's happening when you take your shot.

New episodes weekly. Subscribe and visit barrickhealth.com for physician-led weight loss care.

He also breaks down the problem he sees every day: patients being mismanaged on GLP-1s by providers running one size fits all algorithms without understanding the clinical nuance. Patients told they're "maxed out" who have options nobody mentioned. Patients who think the medication failed when the care is what failed.

In this episode:

• Dr. Barrick's 80+ lbs. weight loss story on tirzepatide
• What "food noise" is and what it feels like when it stops
• Lessons from treating thousands of GLP-1 patients
• The Kevin story: told he was "maxed out," lost another 9%
• Why access to GLP-1s without expertise is failing patients
• What to expect from future episodes of Straight Shot

This is the show where an obesity medicine doctor who takes the medication himself gives you the information your doctor doesn't have time to explain. No hedging. No corporate script. Just the straight shot.

New episodes weekly. Visit barrickhealth.com for physician-led weight loss care.